25I-NB4OMe

25I-NB4OMe (also known as 2C-I-NB4OMe or Cimbi-31) is a psychedelic phenethylamine and derivative of the psychedelic phenethylamine 2C-I. It was first synthesized by a team at the University of Copenhagen led by David E. Nichols and is part of a series of NBOMe compounds that include 25I-NBOMe and 25C-NBOMe.

Chemistry

25I-NB4OMe is a derivative of the phenethylamine 2C-I, which itself is a derivative of the naturally occurring psychedelic mescaline. The NB4OMe in its name refers to the N-benzylmethoxy group present in its structure. This group is responsible for the compound's high potency and its specific binding to the 5-HT2A receptor, which is thought to be the primary target for psychedelic activity.

Pharmacology

The pharmacology of 25I-NB4OMe is not fully understood. However, it is known to act as a highly potent partial agonist for the 5-HT2A receptor. The psychedelic effects are believed to come from its efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.

Effects

The effects of 25I-NB4OMe are similar to those of other psychedelic phenethylamines, and include open and closed eye visuals, euphoria, time distortion, enhanced introspection, and ego loss. However, due to its high potency and selectivity for the 5-HT2A receptor, it may also produce more undesirable effects such as anxiety, paranoia, and potentially harmful physical effects such as vasoconstriction and tachycardia.

Legality

The legality of 25I-NB4OMe varies by country. In many countries, it is a controlled substance, due to its potential for abuse and the health risks associated with its use. However, in some countries, it remains legal, often due to a lack of specific legislation covering its use and sale.

See also

• 25I-NBOMe
• 25C-NBOMe
• 2C-I
• Psychedelic phenethylamine